EPC Live Program 9.07.25

Clinical Update for Non-Cystic Fibrosis Bronchiectasis: Strategies to Manage Exacerbations and Lung Function
Supported by an independent education grant from Insmed

1. Which of the following should be considerations when evaluating a patient for bronchiectasis?

2. Which of the following medications should be considered for treatment of this patients slow respiratory decline?

Update on Long-Acting Nebulizers for Guideline-Based Maintenance Treatments for Patients with COPD
Supported by an independent education grant from Viatris Specialty LLC

Therapeutic Update on COPD with Type 2 Inflammation
Supported by an independent education grant from GSK

3. What proportion of patients who experience a severe COPD exacerbation are re-hospitalized within 30 days?

4. Which of the following should be the initial pharmacologic treatment plan for a patient diagnosed with COPD who is in GOLD group E?

5. In the Phase 3 MATINEE trial, treatment with Mepolizumab was associated with reductions in COPD exacerbations of:

Name

First NameLast Name

Email

example@example.com

What is your license?

What is your specialty?

Other

What is your practice setting?

Other

How many patients do you typically see each month?

Please rate the extent to which this activity met the following objectives:

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Review the current clinical trial data for therapeutic options to manage NCFBE
Analyze clinical strategies to apply the most appropriate therapeutic options to improve outcomes for patients with NCFBE
Review the updated 2025 GOLD guidelines for the management of patients with moderate-to-severe COPD and their implications for guideline-driven care
Analyze current clinical trial data for LAMA nebulizer therapeutic options to manage COPD
Review clinical strategies to apply guideline- driven long-acting nebulizer treatments for the maintenance of patients with moderate-to-severe COPD
Describe updates to the latest iteration of GOLD guidelines that outline optimal diagnostic and treatment procedures for individuals with type 2 eosinophilic COPD
Assess the efficacy, safety, and mechanisms of action of newly approved and emerging pharmacotherapy for patients with type 2 eosinophilic COPD
Select the most appropriate therapeutic strategy for patients with type 2 eosinophilic COPD on the basis of relevant clinical factors

Please provide us with feedback regarding your experience at the activity:

Rows	Poor	Fair	Good	Very Good	Excellent
Overall Program
Content
Usefulness

Please rate the faculty on their overall teaching ability:

Rows	Poor	Fair	Good	Very Good	Excellent
Jeffrey Hoag, MD
Nicola Hanania, MD

Do you feel this activity was fair balanced and free of commercial bias?

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

What factors beyond clinical care that effect the health of your patients does your team experience?

Date

Attestation: This activity is certified for a maximum of 1.5 AMA PRA Category 1 Credits™.

I participated in this activity and claim _______ credit(s).

PRE-TEST QUESTIONNAIRE

POST-TEST ASSESSMENT